Our 2018 antibiogram, which compiles antimicrobial resistance data from GLA isolates from the calendar year 2018 is now available here. Overall resistance patterns are largely stable compared to 2017 with a few caveats (see below).
For Gram-negative rods in the hospital setting:
Amikacin resistance remains very low and so is still the most active agent vs. multi-drug resistant Gram-negative rod infections at GLA.
Carbapenem-resistant Enterobacteriaceae remain somewhat uncommon at GLA.
There is not much overall difference between piperacillin-tazobactam, cefepime, and meropenem for most Enterobacteriaceae and Pseudomonas (all are better than fluoroquinolones), though there has been a slight decrease in susceptibility to cefepime among all nosocomial non-urine isolates. Please note that >30% nosocomial Pseudomonas isolates are resistant to meropenem.
Ceftriaxone resistance is increasing among all nosocomial E. coli isolates (non-urine: 47% vs. 19% from 2017; urine: 36% vs. 26% from 2017)
Pseudomonas is less frequently encountered in the urine as compared to other sites.
For Gram-negative rods in the outpatient setting:
While cephalexin and cefadroxil remain first-line options for outpatient UTI treatment at GLA, our outpatient E. coli urinary isolate cefazolin susceptibility has decreased to 77% according to breakpoints established for serum (was 92% in 2017). We are in the process of determining susceptibility according to breakpoints established for urine (which are much higher).
Fluoroquinolones and TMP-SMX susceptibilities remain similar (~75-80%).
Key trends among Gram-positive isolates:
MRSA remains quite common (~60% of nosocomial non-blood isolates, ~30% of nosocomial blood isolates, and ~40% of outpatient isolates).
Doxycycline resistance decreased among non-blood nosocomial S. aureus isolates (19% vs. 30%) from 2017.